Posted by Michael Wonder on 07 Dec 2016
Theravance Biopharma receives FDA fast track designation for velusetrag (TD-5108) for idiopathic and diabetic gastroparesis
6 December 2016 - Results from ongoing phase 2b study in gastroparesis expected in mid 2017.
Theravance Biopharma today announced that the U.S. FDA has granted fast track designation to velusetrag (TD-5108) for the treatment of symptoms associated with idiopathic and diabetic gastroparesis.
Velusetrag is an oral investigational drug in development for the treatment of patients with gastroparesis, and is currently being studied in a large, multinational phase 2b study in patients with confirmed gastroparesis of either diabetic or idiopathic origin.
